FilingsTodayKorea Pharma
At a glance
Korea Pharma filed 25 disclosures in the last 12 months, including 8 5% holder, 1 buyback and 1 issuance. The most recent key filing was on Oct 2.
Revenue for 2025 was ₩87.6B, up 7.8% on 2024. It made an operating loss of ₩887.3M. Debt was 84% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩50.5B and operating profit of ₩3.5B.
The 2025 annual report lists 284 employees with an average tenure of 8.5 years and average pay of ₩67.6M, #665 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩132.5M each on average. It paid ₩50 per common share in cash dividends, against ₩50 a year earlier (+0%). 박재돈 and related parties held 64.09% at year end.
From the 2025 annual report
Staff: 284 (186 men, 98 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩19.2B. Directors and auditors: 6, paid ₩1.1B in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩50 | ₩50 | ₩50 |
| Yield (as filed) | 0.40% | 0.30% | 0.20% |
| Total cash dividends | ₩545M | ₩545M | ₩545M |
Largest shareholder
박재돈 holds 25.12%; with 14 related parties the group holds 64.09% of common shares at year end (from 64.59% at the start of the year).
Auditor: 신한회계법인 · opinion: Unqualified.
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.